IFNG and neoplasm: For example, MSCs genetically modified to express interleukin-12 (MSC-IL-12) demonstrated more prominent tumor-specific T-cell responses and anticancer impacts, and also more sustained expressions of IL-12 and interferon (IFN)-γ in both sera and tumor sites than IL-12-expressing viral vector therapy in murine with metastatic tumors (Seo S.H. et al., 2011).